Turkey Blood Bags Market, By Product Type (Single Blood Bag, Double Blood Bag, Triple Blood Bag, Quadruple Blood Bag, Penta Blood Bag), By Type (Collection Bag, Transfer Bag), By Volume (100ml, 150ml, 250ml, 300ml, 350ml, 400ml, 450ml, 500ml), By Material (PVC, PET, Others), By End User (Hospitals, Clinics, Ambulatory Surgical Center, Blood Banks, Others), By Region, Competition, Forecast & Opportunities, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 30.23 Million
CAGR (2026-2031)	5.67%
Fastest Growing Segment	Triple Blood Bag
Largest Market	Marmara
Market Size (2031)	USD 42.09 Million

Market Overview

The Turkey Blood Bags Market will grow from USD 30.23 Million in 2025 to USD 42.09 Million by 2031 at a 5.67% CAGR. Blood bags are sterile, single-use medical devices indispensable for the safe collection, storage, processing, and transfusion of whole blood and its constituent components. The Turkey blood bags market is primarily driven by the escalating prevalence of chronic diseases necessitating transfusions, a rising incidence of trauma cases, and the continuous expansion of healthcare infrastructure. Concurrently, a growing emphasis on voluntary blood donation significantly supports market demand, with the Turkish Red Crescent reporting that approximately 3.04 million units of donated blood were collected in 2025.

Despite these robust growth drivers, a significant challenge impeding market expansion in Turkey is the presence of stringent regulatory requirements. Adherence to evolving national and international standards for product safety, manufacturing, and distribution necessitates substantial investment in compliance and quality assurance, potentially escalating operational costs for manufacturers and delaying market entry for innovative products.

Key Market Drivers

Healthcare Infrastructure Expansion Driving Blood Bag Demand
Expanding healthcare infrastructure and investment significantly propels the Turkey Blood Bags Market. Continuous government initiatives aimed at modernizing and expanding the national healthcare network directly translate into increased demand for blood bags. New hospital constructions and upgrades to existing facilities enhance the capacity for complex medical procedures and emergency care, both of which require readily available blood products. For instance, the Ondokuz Mayıs University (OMU) new hospital project, designed with an 800-bed capacity, was officially included in the 2026 Investment Program, signaling sustained growth in medical facility development across the country. This expansion not only improves accessibility to healthcare services but also supports a higher volume of patient treatments requiring transfusions.

Surgical Procedures and Medical Tourism Fuel Blood Bag Demand
The growth in surgical procedures and medical tourism further contributes substantially to the market. Turkey has emerged as a prominent destination for international patients seeking various medical treatments, including a wide array of surgical interventions. These procedures inherently necessitate a robust supply of blood and its components, thereby driving the demand for blood bags. According to Hürriyet Daily News, in April 2026, official figures indicated that 1.39 million foreign patients traveled to Türkiye for medical services in 2025. This influx of medical tourists, combined with a rising domestic surgical caseload, directly increases the utilization of blood bags. Overall, the consistent efforts in blood collection by organizations like the Turkish Red Crescent are vital; according to Daily Sabah, in June 2026, the organization collected over 1.2 million units of blood during the first five months of 2026, demonstrating ongoing efforts to meet this demand.

Download Free Sample Report

Key Market Challenges

Regulatory requirements raise costs and constrain market growth
The challenging factor impeding the growth of the Turkey blood bags market is the presence of stringent regulatory requirements. Adherence to these evolving national and international standards for product safety, manufacturing, and distribution directly escalates operational costs for manufacturers. This necessitates substantial investment in compliance and quality assurance, impacting the profitability and financial planning of companies operating within the sector.

Turkey-specific regulatory complexity causes market-entry delays and compliance burdens
The complexity of the regulatory landscape, which includes Turkey-specific requirements such as the Ürün Takip Sistemi (ÜTS) for electronic registration and traceability, further complicates market entry and operations. Even for products with CE marking, additional local obligations, including the appointment of a Turkish authorized representative and dossier translations, can lead to significant market-access delays for innovative products. This protracted process reduces the speed at which new technologies can reach patients and limits market expansion. It has not been possible to obtain specific statistical numerical data from a Turkish industrial association within the last year quantifying the direct cost or duration of these regulatory delays for the blood bags market.

Key Market Trends

DEHP-Free Blood Bags: Safety and Regulatory Alignment in Turkey
Emphasis on DEHP-Free Blood Bag Formulations represents a critical shift driven by increasing awareness of patient safety concerns associated with traditional plasticizers. Diethylhexyl phthalate (DEHP), commonly used in PVC blood bags, has been linked to potential health risks, especially for vulnerable patient groups such as neonates or those undergoing long-term transfusions. This has led to a proactive move by manufacturers and healthcare providers in Turkey to adopt alternative, safer materials and formulations. The transition towards DEHP-free products is influencing procurement strategies and product development within the market, aiming to mitigate potential exposure risks and align with evolving international safety standards. The regulatory environment in Turkey is increasingly aligning with European Union directives regarding medical devices. For instance, the EU's ban on DEHP in blood bags by May 27, 2025, necessitates a shift towards DEHP-free products, reflecting a significant policy influence on the Turkish market.

Multi-Compartment Blood Bags: Enhancing Processing and Inventory in Turkey
The increased use of multi-compartment blood bags is another significant trend, enhancing the efficiency and safety of blood component processing. These innovative bags facilitate the sterile separation of whole blood into its constituent components—such as red blood cells, plasma, and platelets—within a closed system, minimizing contamination risks and optimizing storage conditions. This capability is vital for Turkish blood centers and hospitals, allowing for more targeted transfusions and reducing wastage by maximizing the therapeutic value of each donation. The adoption of multi-compartment technology supports improved inventory management and better patient outcomes by ensuring the availability of specific blood components as needed. The Turkish Red Crescent (Kızılay) has consistently focused on optimizing blood collection and processing, with the organization collecting over 1.2 million units of blood during the first five months of 2026. This volume underscores the ongoing need for efficient processing solutions like multi-compartment bags to manage diverse blood components.

Segmental Insights

Triple Blood Bag Growth Fueled by Component Therapy and Modernization Efforts
The Turkey Blood Bags Market is experiencing significant expansion, with the Triple Blood Bag segment emerging as the fastest-growing category. This rapid growth is primarily attributed to the increasing emphasis on component therapy, necessitating the efficient separation and storage of red blood cells, plasma, and platelets from a single donation. The Turkish Red Crescent (Türk Kızılay), a key institution in the nation's blood services, actively drives the modernization of blood collection and processing standards to ensure a safe and advanced blood supply for the country. This commitment to evolving blood banking practices and improving healthcare infrastructure fuels the adoption of sophisticated blood bag systems, enhancing patient care outcomes across Turkey.

Regional Insights

Marmara Region Leads Blood Bags Market Through Strong Healthcare Infrastructure and Donor Network
The Marmara region leads the Turkey Blood Bags Market due to its strategic geographical positioning and highly developed healthcare infrastructure. This dominance stems from a significant concentration of advanced public and private hospitals, particularly in urban centers like Istanbul, which attract considerable investment in medical facilities. The region's substantial population density contributes to a consistently high demand for blood and blood products, driven by numerous medical procedures, trauma cases, and the management of chronic diseases. Furthermore, institutions such as the Turkish Red Crescent, which manages the national blood supply, have a strong operational presence and facilitate a robust donor base within Marmara, ensuring a steady collection and distribution network for blood bags.

Recent Developments

• In December 2025, SEM Group advanced its SEM Biotech Vacuum Sterile Blood Collection Tube Manufacturing Facility in Istanbul, marking key developmental milestones. The company affirmed the facility's adherence to stringent global standards, including ISO 13485 and ISO 6710, crucial for quality assurance in medical device production. This USD 20 million investment aimed to bolster Turkey's domestic manufacturing capabilities for hundreds of millions of blood collection tubes annually, thereby reducing reliance on imports. While focusing on tubes, this development is integral to the broader blood collection and preparation process, which directly precedes the use of blood bags for storage and transfusion within the Turkey Blood Bags Market.
• In November 2025, SK plasma, a South Korean biopharmaceutical company, and the Turkish Red Crescent (Kizilay) entered into a strategic collaboration by signing a shareholders' agreement in Ankara. This agreement established a joint venture named Proturk, with the primary objective of constructing a plasma-derived medicinal products (PDMP) plant in Turkey. The facility is designed to process 600,000 liters of plasma annually. This initiative represents a significant step towards securing national self-sufficiency for essential medicines derived from blood components, directly impacting the demand for efficient blood collection and processing systems, including various types of blood bags, within Turkey's healthcare infrastructure.
• In September 2025, the Turkish Health Ministry announced the launch of a national tissue and cell banking system, focusing on domestic production to meet patient requirements. This innovative system facilitated the in-country manufacturing of personalized tissue and cell products. The ministry emphasized that this national infrastructure, which includes the meticulous collection of human-derived materials under strict biosafety standards, operates on principles comparable to a traditional blood bank. This advancement is anticipated to stimulate demand for specialized collection and storage containers, similar to advanced blood bags, as Turkey continues to develop its local production capabilities for critical medical products.
• In 2025, Kızılay Biomedical, an affiliated entity of the Turkish Red Crescent, embarked on a strategic plan to establish domestic blood bag production in Turkey. This significant investment aimed to mitigate the nation's reliance on annual imports of approximately 3 million blood bag sets, which are essential for maintaining the country's blood supply. The company announced its intention to achieve an annual production capacity of 3 million blood bag sets from a 21,000 m² facility located in Çatalca. This initiative is pivotal for enhancing self-sufficiency and ensuring a stable, high-quality supply of vital medical consumables for the Turkey Blood Bags Market.

Key Market Players

• Fresenius Kabi AG
• Terumo Corporation
• Haemonetics Corporation
• Macopharma
• Grifols S.A.
• Bıçakcılar Tıbbi Cihazlar Sanayi ve Ticaret A.Ş.
• JMS Co., Ltd.
• Nipro Corporation
• Shandong Taishan Medical Device Co., Ltd.
• Kangjian Medical Apparatus Co., Ltd.

By Product Type	By Type	By Volume	By Material	By End User	By Region
Single Blood Bag Double Blood Bag Triple Blood Bag Quadruple Blood Bag Penta Blood Bag	Collection Bag Transfer Bag	100ml 150ml 250ml 300ml 350ml 400ml 450ml 500ml	PVC PET Others	Hospitals Clinics Ambulatory Surgical Center Blood Banks Others	Marmara Central Anatolia Aegean Mediterranean Black Sea South-Eastern Anatolia Eastern Anatolia

Report Scope:

In this report, the Turkey Blood Bags Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Turkey Blood Bags Market, By Product Type:

• Single Blood Bag
• Double Blood Bag
• Triple Blood Bag
• Quadruple Blood Bag
• Penta Blood Bag

• Turkey Blood Bags Market, By Type:

• Collection Bag
• Transfer Bag

• Turkey Blood Bags Market, By Volume:

• 100ml
• 150ml
• 250ml
• 300ml
• 350ml
• 400ml
• 450ml
• 500ml

• Turkey Blood Bags Market, By Material:

• PVC
• PET
• Others

• Turkey Blood Bags Market, By End User:

• Hospitals
• Clinics
• Ambulatory Surgical Center
• Blood Banks
• Others

• Turkey Blood Bags Market, By Region:

• Marmara
• Central Anatolia
• Aegean
• Mediterranean
• Black Sea
• South-Eastern Anatolia
• Eastern Anatolia